北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 消化内科  > 期刊论文
学科主题: 临床医学
题名:
Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells
作者: Peng, Meiyu1,2,3,4; Huang, Bingqing1,2,3; Zhang, Qi5; Fu, Shuyu1,2,3; Wang, Dan1,2,3; Cheng, Xixi1,2,3; Wu, Xi1,2,3; Xue, Zhenyi1,2,3; Zhang, Lijuan1,2,3; Zhang, Da6; Da, Yurong1,2; Dai, Yun3,7; Yang, Qing8; Yao, Zhi1,2,3; Qiao, Liang9; Zhang, Rongxin1,2,3
关键词: Pancreatic cancer ; Embelin ; Inflammation ; IL-6 ; MDSCs
刊名: CANCER LETTERS
发表日期: 2014-11-28
DOI: 10.1016/j.canlet.2014.08.011
卷: 354, 期:2, 页:407-416
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: TH17 CELLS ; ACTIVATION ; DIFFERENTIATION ; CONTRIBUTES ; TUMORS ; CSF
英文摘要:

Pancreatic cancer is an aggressive malignancy and unresponsive to conventional chemotherapies. Here, the anti-inflammatory and anti-tumor effects of embelin on pancreatic cancer were investigated. Embelin significantly attenuated cells invasion, proliferation and induced apoptosis through inhibition of STAT3 and activation of p53 signaling pathways. Embelin substantially reduced the tumorigenicity of pancreatic cancer cells in vivo, which was associated with reduced inflammatory cells and immune suppressive cells, IL-17A(+) Th17, GM-CSF+ Th, MDSCs and Treg, through inhibition of IL-6 secretion. Moreover, embelin decrease IL-6-induced STAT3 phosphorylation. In summary, embelin represents a novel therapeutic drug candidate for the clinical treatment of pancreatic cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

语种: 英语
所属项目编号: 2012CB932503 ; 2011CB933100 ; 91029705 ; 81172864 ; 81272317 ; 81371644 ; 81072019
项目资助者: Chinese Ministry of Science and Technology ; National Natural Science Foundation of China
WOS记录号: WOS:000344127600022
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65892
Appears in Collections:北京大学第一临床医学院_消化内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Weifang Med Univ, Basic Med Coll, Dept Immunol, Weifang, Peoples R China
2.Tianjin Med Univ, Res Ctr Basic Med Sci, Lab Immunol & Inflammat, Tianjin, Peoples R China
3.Tianjin Med Univ, Basic Med Coll, Dept Immunol, Tianjin, Peoples R China
4.Tianjin Med Univ, Key Lab Immune Microenvironm & Dis, Educ Minist China, Tianjin, Peoples R China
5.Tianjin Med Univ, Sch Basic Med Sci, Dept Pharmacol, Tianjin, Peoples R China
6.Tianjin Med Univ, Sch Med Imaging, Tianjin 300070, Peoples R China
7.Peking Univ, Hosp 1, Dept Gastroenterol, Beijing, Peoples R China
8.Tianjin Med Univ, Canc Hosp, Dept Genitourinary Oncol, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
9.Univ Sydney, Westmead Hosp, Western Clin Sch, Westmead Millennium Inst,Storr Liver Unit, Westmead, NSW 2145, Australia

Recommended Citation:
Peng, Meiyu,Huang, Bingqing,Zhang, Qi,et al. Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells[J]. CANCER LETTERS,2014,354(2):407-416.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Peng, Meiyu]'s Articles
[Huang, Bingqing]'s Articles
[Zhang, Qi]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Peng, Meiyu]‘s Articles
[Huang, Bingqing]‘s Articles
[Zhang, Qi]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace